Genistein prevents bone loss in type 2 diabetic rats induced by streptozotocin
Open Access
- 9 December 2020
- journal article
- research article
- Published by SNF Swedish Nutrition Foundation in Food & Nutrition Research
Abstract
Background: Diabetic osteoporosis has become a severe public health problem in the aging societies. Genistein has been reported to play an important role in preventing and treating metabolic diseases via its anti-inflammatory, antioxidant, anti-estrogenic, and estrogen-like functions. Objective: We aimed to investigate whether genistein exerts bone-protective effect on diabetic rats induced by 35 mg/kg streptozotocin (STZ) plus a 4-week high-fat diet. Design: Sprague–Dawley rats were randomly divided into four groups: (1) control group, (2) type 2 diabetes mellitus (T2DM) model group, (3) T2DM with 10 mg/kg genistein, and (4) T2DM with 30 mg/kg genistein. After an 8-week treatment with genistein, the femurs, tibias, and blood were collected from all rats for further analysis. Results: Genistein at 10 mg/kg showed little effect on diabetic osteoporosis, whereas genistein at 30 mg/kg significantly improved glucose and bone metabolisms compared with diabetic rats. Our results showed that 30 mg/ kg genistein significantly increased bone mineral density, serum osteocalcin, and bone alkaline phosphatase. Genistein also effectively lowered fasting blood glucose, tartrate-resistant acid phosphatase 5b, tumor necrosis factor-α, interleukin-6, and numbers of adipocytes and osteoclasts. Compared with the T2DM group, protein levels of receptor activator of nuclear factor κB ligand (RANKL) and peroxisome proliferator-activated receptor- γ (PPAR-γ) were decreased, while protein levels of osteoprotegerin (OPG), β-catenin, and runt-related transcription factor 2 (Runx-2) were increased after genistein intervention. Conclusion: Genistein could effectively improve abnormal bone metabolism in STZ-induced diabetic rats; the underlying molecular mechanisms might be related to OPG/RANKL, PPAR-γ, and β-catenin/Runx-2 pathways.Keywords
This publication has 48 references indexed in Scilit:
- Effect of genistein, a natural soy isoflavone, on pancreatic β-cells of streptozotocin-induced diabetic rats: Histological and immunohistochemical studyJournal of Microscopy and Ultrastructure, 2015
- Bone damage in type 2 diabetes mellitusNutrition, Metabolism and Cardiovascular Diseases, 2014
- Systematic review and meta-analysis of the bone protective effect of phytoestrogens on osteoporosis in ovariectomized ratsNutrition Research, 2014
- Modeling type 2 diabetes in rats using high fat diet and streptozotocinJournal of Diabetes Investigation, 2014
- Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (Review)Molecular Medicine Reports, 2014
- High glucose concentrations alter the biomineralization process in human osteoblastic cellsBone, 2012
- Bone turnover markers for osteoporotic status assessment? A systematic review of their diagnosis value at baseline in osteoporosisJoint Bone Spine, 2012
- Dose-dependent effects of genistein on bone homeostasis in rats' mandibular subchondral boneActa Pharmacologica Sinica, 2011
- High Levels of Tumor Necrosis Factor-α Contribute to Accelerated Loss of Cartilage in Diabetic Fracture HealingThe American Journal of Pathology, 2009
- An estimate of the worldwide prevalence and disability associated with osteoporotic fracturesOsteoporosis International, 2006